Key facts
- It has raised $400K; the latest was Early Stage VC ($400K) in Nov 2025.
- Notable investors include Gaingels, Calm Ventures, Endless Frontier Labs, NFX, YZi Labs — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for RenewalBio
- ·The full record, as it builds
Funding rounds
No funding rounds for RenewalBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RenewalBio
Developer of a synthetic-embryo and stem-cell therapeutics platform intended to generate transplantable tissues and rejuvenated cells. The company offers patient-specific stem-cell systems, embryo-model generation from naïve pluripotent stem cells, and protocols for early-human-development modelling with aims in infertility, organ replacement, and longevity therapies, enabling researchers and clinicians to access novel cell- and tissue-sources for regenerative medicine.
- Sector
- Healthcare
- HQ
- Rehovot, Israel
- Founded
- 2022
- Employees
- 8
- Website
- renewal.bio/
- Ownership
- Privately Held (backing)
RenewalBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RenewalBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RenewalBio in its N-PORT filings yet. We sweep new filings monthly.